{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T18:38:14Z","timestamp":1696358294421},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T00:00:00Z","timestamp":1171670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2007,4,4]]},"DOI":"10.1007\/s11102-007-0009-y","type":"journal-article","created":{"date-parts":[[2007,2,16]],"date-time":"2007-02-16T15:22:07Z","timestamp":1171639327000},"page":"95-101","source":"Crossref","is-referenced-by-count":8,"title":["Clinical presentation and response to therapy in patients with massive prolactin hypersecretion"],"prefix":"10.1007","volume":"10","author":[{"given":"Susana","family":"Mascarell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Sarne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,2,17]]},"reference":[{"issue":"3","key":"9_CR1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0889-8529(05)70203-6","volume":"30","author":"ME Molitch","year":"2001","unstructured":"Molitch ME (2001) Disorders of prolactin secretion. Endocrinol Metab Clin North Am 30(3):585\u2013610","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"9_CR2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0889-8529(05)70056-6","volume":"28","author":"SL Asa","year":"1999","unstructured":"Asa SL (1999) The pathology of pituitary tumors. Endocrinol Metab Clin North Am 28(1):13\u2013vi","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"9_CR3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s002340050657","volume":"40","author":"C Majos","year":"1998","unstructured":"Majos C, Coll S, Aguilera C, Acebes JJ, Pons LC (1998) Imaging of giant pituitary adenomas. Neuroradiology 40(10):651\u2013655","journal-title":"Neuroradiology"},{"issue":"2","key":"9_CR4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3171\/jns.2002.97.2.0299","volume":"97","author":"RK Shrivastava","year":"2002","unstructured":"Shrivastava RK, Arginteanu MS, King WA, Post KD (2002) Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97(2):299\u2013306","journal-title":"J Neurosurg"},{"issue":"6","key":"9_CR5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7326\/0003-4819-129-6-199809150-00009","volume":"129","author":"I Shimon","year":"1998","unstructured":"Shimon I, Melmed S (1998) Management of pituitary tumors. Ann Intern Med 129(6):472\u2013483","journal-title":"Ann Intern Med"},{"issue":"1","key":"9_CR6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00004728-198402000-00027","volume":"8","author":"D Perani","year":"1984","unstructured":"Perani D, Colombo N, Scotti G, Tonon C (1984) Rapid size reduction of giant prolactinoma following medical treatment. J Comput Assist Tomogr 8(1):131\u2013133","journal-title":"J Comput Assist Tomogr"},{"issue":"3","key":"9_CR7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2265.1996.663486.x","volume":"44","author":"E St Jean","year":"1996","unstructured":"St Jean E, Blain F, Comtois R (1996) High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 44(3):305\u2013309","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"9_CR8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF03347299","volume":"21","author":"MS Petakov","year":"1998","unstructured":"Petakov MS, Damjanovic SS, Nikolic-Durovic MM, et al (1998) Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 21(3):184\u2013188","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"9_CR9","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1212\/WNL.55.9.1415","volume":"55","author":"P Pakzaban","year":"2000","unstructured":"Pakzaban P (2000) Giant prolactinoma and hook effect. Neurology 55(9):1415\u20131416","journal-title":"Neurology"},{"issue":"1\u20132","key":"9_CR10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000182496","volume":"38","author":"T Brue","year":"1992","unstructured":"Brue T, Pellegrini I, Priou A, Morange I, Jaquet P (1992) Prolactinomas and resistance to dopamine agonists. Horm Res 38(1\u20132):84\u201389","journal-title":"Horm Res"},{"issue":"4","key":"9_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1507\/endocrj.45.529","volume":"45","author":"N Saeki","year":"1998","unstructured":"Saeki N, Nakamura M, Sunami K, Yamaura A (1998) Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 45(4):529\u2013537","journal-title":"Endocr J"},{"issue":"2","key":"9_CR12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13(2):220\u2013240","journal-title":"Endocr Rev"},{"issue":"1","key":"9_CR13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0889-8529(05)70061-X","volume":"28","author":"ME Molitch","year":"1999","unstructured":"Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 28(1):143\u201369, vii","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"9_CR14","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2002-020426","volume":"87","author":"MP Gillam","year":"2002","unstructured":"Gillam MP, Middler S, Freed DJ, Molitch ME (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87(10):4447\u20134451","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9_CR15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0015-0282(16)53154-9","volume":"52","author":"E Ciccarelli","year":"1989","unstructured":"Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser GM, Grossman A (1989) Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia. Fertil Steril 52(6):930\u2013935","journal-title":"Fertil Steril"},{"issue":"275","key":"9_CR16","first-page":"227","volume":"74","author":"JR Davis","year":"1990","unstructured":"Davis JR, Sheppard MC, Heath DA (1990) Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med 74(275):227\u2013238","journal-title":"Q J Med"},{"issue":"4","key":"9_CR17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0090-3019(92)90153-E","volume":"37","author":"Y Iwai","year":"1992","unstructured":"Iwai Y, Hakuba A, Khosla VK, et al (1992) Giant basal prolactinoma extending into the nasal cavity. Surg Neurol 37(4):280\u2013283","journal-title":"Surg Neurol"},{"issue":"931","key":"9_CR18","first-page":"129","volume":"105","author":"SK Grebe","year":"1992","unstructured":"Grebe SK, Delahunt JW, Feek CM (1992) Treatment of extensively invasive (giant) prolactinomas with bromocriptine. N Z Med J 105(931):129\u2013131","journal-title":"N Z Med J"},{"issue":"2","key":"9_CR19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1210\/jcem-64-2-391","volume":"64","author":"JC Prior","year":"1987","unstructured":"Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64(2):391\u2013394","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1011412028660","volume":"3","author":"JJ Orrego","year":"2000","unstructured":"Orrego JJ, Chandler WF, Barkan AL (2000) Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 3(3):189\u2013192","journal-title":"Pituitary"},{"issue":"3","key":"9_CR21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/jnnp.63.3.295","volume":"63","author":"U Reuter","year":"1997","unstructured":"Reuter U, Mehraein S, Arnold G, Lehmann R (1997) Neurological picture. A \u201cgiant\u201d prolactinoma. J Neurol Neurosurg Psychiatry 63(3):295","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6333","key":"9_CR22","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1136\/bmj.284.6333.1908","volume":"284","author":"JA Wass","year":"1982","unstructured":"Wass JA, Williams J, Charlesworth M, et al (1982) Bromocriptine in management of large pituitary tumours. Br Med J (Clin Res Ed) 284(6333):1908\u20131911","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"4","key":"9_CR23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1012836331506","volume":"3","author":"JJ Orrego","year":"2000","unstructured":"Orrego JJ, Chandler WF, Barkan AL (2000) Pergolide as primary therapy for macroprolactinomas. Pituitary 3(4):251\u2013256","journal-title":"Pituitary"},{"issue":"4","key":"9_CR24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/00006123-199804000-00126","volume":"42","author":"AL Barkan","year":"1998","unstructured":"Barkan AL, Chandler WF (1998) Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the \u201chigh-dose hook effect\u201d: case report. Neurosurgery 42(4):913\u2013915","journal-title":"Neurosurgery"},{"key":"9_CR25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11102-005-5087-0","volume":"8","author":"C Yu","year":"2005","unstructured":"Yu C, Wu Z, Gong J (2005) Combined treatment of invasive giant prolactinomas. Pituitary 8:61\u201365","journal-title":"Pituitary"},{"key":"9_CR26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3171\/jns.2006.104.1.54","volume":"104","author":"ZB Wu","year":"2006","unstructured":"Wu ZB, Yu CJ, Su ZP,Shuge QC, Wu JS, Zheng WM (2006) Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 104:54\u201361","journal-title":"J Neurosurg"},{"key":"9_CR27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11102-005-5111-4","volume":"8","author":"A Chattopadhyay","year":"2005","unstructured":"Chattopadhyay A, Bhansali A, Masoodi SR (2005) Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 8:147\u2013154","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-007-0009-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-007-0009-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-007-0009-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T06:08:03Z","timestamp":1559369283000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-007-0009-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,4,4]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1007\/s11102-007-0009-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,17]]}}}